Russell Investments Group Ltd. Sells 85,534 Shares of Edwards Lifesciences Corporation $EW

Russell Investments Group Ltd. lowered its position in Edwards Lifesciences Corporation (NYSE:EW) by 4.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,822,386 shares of the medical research company’s stock after selling 85,534 shares during the period. Russell Investments Group Ltd.’s holdings in Edwards Lifesciences were worth $155,489,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Kemnay Advisory Services Inc. purchased a new stake in Edwards Lifesciences in the 4th quarter valued at about $27,000. Arthur M. Cohen & Associates LLC boosted its stake in shares of Edwards Lifesciences by 3.2% in the 4th quarter. Arthur M. Cohen & Associates LLC now owns 11,783 shares of the medical research company’s stock worth $1,005,000 after buying an additional 365 shares during the last quarter. Captrust Financial Advisors grew its holdings in shares of Edwards Lifesciences by 1.9% in the fourth quarter. Captrust Financial Advisors now owns 59,171 shares of the medical research company’s stock valued at $5,044,000 after acquiring an additional 1,122 shares in the last quarter. Artisan Partners Limited Partnership bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $99,462,000. Finally, &PARTNERS increased its position in shares of Edwards Lifesciences by 3.3% during the fourth quarter. &PARTNERS now owns 24,873 shares of the medical research company’s stock valued at $2,120,000 after acquiring an additional 806 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on EW. Robert W. Baird lifted their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a report on Friday, April 24th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $100.00 target price on shares of Edwards Lifesciences in a research report on Tuesday. Barclays reiterated an “overweight” rating and set a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Truist Financial set a $90.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Finally, Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $95.96.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 620 shares of the stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $81.14, for a total transaction of $50,306.80. Following the transaction, the vice president owned 40,411 shares of the company’s stock, valued at $3,278,948.54. This represents a 1.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 81,038 shares of company stock valued at $6,683,255. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $88.56 on Wednesday. The business’s 50 day simple moving average is $83.03 and its 200 day simple moving average is $83.11. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $89.60. The company has a market cap of $51.00 billion, a price-to-earnings ratio of 47.11, a PEG ratio of 2.16 and a beta of 0.87. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. During the same period last year, the business posted $0.64 earnings per share. The business’s revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Sell-side analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.